Core One Labs Inc. (CLABF)
OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
Feb 11, 2026, 9:30 AM EST
Core One Labs Revenue
In the fiscal year ending March 31, 2023, Core One Labs had annual revenue of 458.54K CAD, down -29.25%. Core One Labs had revenue of 93.66K in the quarter ending December 31, 2023, a decrease of -17.22%.
Revenue
458.54K CAD
Revenue Growth
-18.65%
P/S Ratio
0.01
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.71K USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2023 | 458.54K | -189.55K | -29.25% |
| Dec 31, 2022 | 648.09K | 216.47K | 50.15% |
| Dec 31, 2021 | 431.62K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ONE Bio | 53.91M |
| Synovics Pharmaceuticals | 19.09M |
| Kaleido Biosciences | 1.10M |
| MultiCell Technologies | 805.24K |
| Theralink Technologies | 635.45K |
| MetaStat | 23.30K |
Core One Labs News
- 5 months ago - CSE Bulletin: Delist - Core One Labs Inc. (COOL) - Newsfile Corp
- 1 year ago - Core One Enters into Loan Agreement with Right Season Investments - Accesswire
- 2 years ago - Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market - Accesswire
- 2 years ago - Core One Labs' Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods - Accesswire
- 2 years ago - Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer's and Parkinson's Disease - Accesswire
- 2 years ago - Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass - Accesswire
- 2 years ago - Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer's and Parkinson's Disease - Accesswire
- 2 years ago - Core One Labs Enters into Letter of Intent for First Sale of Its Psychedelic Compounds - Accesswire